Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bacilac Bifido
- Development stage
- Unknown
- Lead developer
- Ceres Pharma
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bacilac Bifido is a probiotic dietary supplement distributed by Laboratoires Crinex, originally developed by the Belgian laboratory VESALE. It is designed to restore and maintain the balance of the intestinal flora (gut microbiota). The formulation contains a blend of 3.3 billion probiotic bacteria per sachet, including *Bifidobacterium infantis*, *Bifidobacterium longum*, *Bifidobacterium lactis*, *Bifidobacterium bifidum*, and *Lactobacillus rhamnosus*. It is indicated for dietary supplementation and gut microbiota support in adults and children from 3 years of age, particularly during or after antibiotic treatment to prevent dysbiosis.
- Brand names
- BacilacBacilac Bifido
- Other names
- Bacilac/Osmoflore
Beyond the preview
Go deeper on Bacilac Bifido.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bacilac Bifido.